1. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003; 48:314–346.
Article
2. Yoon PS, Singh K. Update on antifibrotic use in glaucoma surgery, including use in trabeculectomy and glaucoma drainage implants and combined cataract and glaucoma surgery. Curr Opin Ophthalmol. 2004; 15:141–146.
Article
3. Cordeiro MF, Chang L, Lim KS, et al. Modulating conjunctival wound healing. Eye (Lond). 2000; 14 Pt 3B:536–547.
Article
4. Mead AL, Wong TT, Cordeiro MF, et al. Evaluation of anti-TGF-β 2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003; 44:3394–3401.
5. Cordeiro MF, Reichel MB, Gay JA, et al. Transforming growth factor-beta 1, -beta 2, and -beta 3 in vivo: effects on normal and mitomycin C-modulated conjunctival scarring. Invest Ophthalmol Vis Sci. 1999; 40:1975–1982.
6. Wang R. Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J. 2002; 16:1792–1798.
7. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev. 2012; 92:791–896.
Article
8. Parra O, Monsó E, Gallego M, Morera J. Inhalation of hydrogen sulphide: a case of subacute manifestations and long term sequelae. Br J Ind Med. 1991; 48:286–287.
Article
9. Duong TX, Suruda AJ, Maier LA. Interstitial fibrosis following hydrogen sulfide exposure. Am J Ind Med. 2001; 40:221–224.
Article
10. Fang LP, Lin Q, Tang CS, Liu XM. Hydrogen sulfide suppresses migration, proliferation and myofibroblast transdifferentiation of human lung fibroblasts. Pulm Pharmacol Ther. 2009; 22:554–561.
Article
11. Sheng J, Shim W, Wei H, et al. Hydrogen sulphide suppresses human atrial fibroblast proliferation and transformation to myofibroblasts. J Cell Mol Med. 2013; 17:1345–1354.
Article
12. Leslie M. Medicine. Nothing rotten about hydrogen sulfide's medical promise. Science. 2008; 320:1155–1157.
Article
13. Li L, Whiteman M, Guan YY, et al. Characterization of a novel, water-soluble hydrogen sulfide releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation. 2008; 117:2351–2360.
14. Baskar R, Bian J. Hydrogen sulfide gas has cell growth regulatory role. Eur J Pharmacol. 2011; 656:5–9.
Article
15. Teunissen BE, Smeets PJ, Willemsen PH, et al. Activation of PPAR delta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts. Cardiovasc Res. 2007; 75:519–529.
16. Björkerud S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. Arteriosclerosis Thromb. 1991; 11:892–902.
Article
17. Skalli O, Schürch W, Seemayer T, et al. Myofibroblasts from diverse pathological settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab Invest. 1989; 60:275–285.
18. Darby I, Skalli O, Gabbiani G. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest. 1990; 63:21–29.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65:55–63.
Article
20. Liu XD, Skold CM, Umino T, et al. Sodium nitroprusside augments human lung fibroblast collagen gel contraction independently of NO-cGMP pathway. Am J Physiol Lung Cell Mol Physiol. 2000; 278:L1032–L1038.
21. Baskar R, Moore PK. Nuclear accumulation and up-regulation of p53 and its associated proteins after H2S treatment in human lung fibroblasts. J Cell Mol Med. 2008; 12:2297–2300.
Article
22. Baskar R, Li L, Moore PK. Hydrogen sulfide-induces DNA damage and changes in apoptotic gene expression in human lung fibroblast cells. FASEB J. 2007; 21:247–255.
Article
23. Shu DY, Lovicu FJ. Myofibroblast transdifferentiation: the dark force in ocular wound healing and fibrosis. Prog Retin Eye Res. 2017; 60:44–65.
Article
24. Cordeiro MF. Beyond mitomycin: TGF-β and wound healing. Prog Retin Eye Res. 2002; 21:75–89.
Article
25. Prendes MA, Harris A, Wirostko BM, et al. The role of transforming growth factor β in glaucoma and the therapeutic implications. Br J Ophthalmol. 2013; 97:680–686.
Article
26. Cunliffe IA, Rees RC, Rennie IG. The effect of TGF-beta 1 and TGF-beta 2 on the proliferation of human Tenon's capsule fibroblasts in tissue culture. Acta Ophthalmol Scand. 1996; 74:31–35.
Article
27. Browning AC, Alibhai A, McIntosh RS, et al. Effect of diabetes mellitus and hyperglycemia on the proliferation of human Tenon's capsule fibroblasts: implications for wound healing after glaucoma drainage surgery. Wound Repair Regen. 2005; 13:295–302.
Article
28. Kay EP, Lee HK, Park KS, Lee SC. Indirect mitogenic effect of transforming growth factor-beta on cell proliferation of subconjunctival fibroblasts. Invest Ophthalmol Vis Sci. 1998; 39:481–486.
29. Denk PO, Hoppe J, Hoppe V, Knorr M. Effect of growth factors on the activation of human Tenon's capsule fibroblasts. Curr Eye Res. 2003; 27:35–44.
Article
30. Desmouliére A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-β induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993; 122:103–111.
31. Olson ER, Naugle JE, Zhang X, et al. Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol. 2005; 288:H1131–H1138.
Article
32. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999; 40:2225–2234.
33. Meyer-ter-Vehn T, Sieprath S, Katzenbergeret B, et al. Contractility as a prerequisite for TGF-β–induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest Ophthalmol Vis Sci. 2006; 47:4895–4904.
Article
34. Desmoulière A, Redard M, Darby I, Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol. 1995; 146:56–66.
35. Kottler UB, Jünemann AG, Aigner T, et al. Comparative effects of TGF-beta 1 and TGF-beta 2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenon's capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma. Exp Eye Res. 2005; 80:121–134.
36. Pierce GF, Mustoe TA, Lingelbach J, et al. Platelet-derived growth factor and transforming growth factor-β enhance tissue repair activities by unique mechanisms. J Cell Biol. 1989; 109:429–440.
37. Li Z, Bergen TV, Van de, et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtering surgery. Invest Ophthalmol Vis Sci. 2009; 50:5217–5225.
38. Zhou X, An G, Chen J. Inhibitory effects of hydrogen sulphide on pulmonary fibrosis in smoking rats via attenuation of oxidative stress and inflammation. J Cell Mol Med. 2014; 18:1098–1103.
39. Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL. The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 2013; 1:45–49.
Article
40. Kim JW, Kim SK, Song IH, Kim IT. Mitomycin C-induced apoptosis in cultured human tenon's capsule fibroblasts. Korean J Ophthalmol. 1999; 13:7–15.
Article
41. Lee SE, Kim JW. Effects of valproic acid on the survival of human tennon's capsule fibroblasts. J Korean Ophthalmol Soc. 2018; 59:1056–1061.
Article
42. Seibold LK, Sherwood MB, Kahook MY. Wound modulation after filtration surgery. Surv Ophthalmol. 2012; 57:530–550.
Article
43. Zada M, Pattamatta U, White A. Modulation of fibroblasts in conjunctival wound healing. Ophthalmology. 2018; 125:179–192.
Article